ReviewBiomedicines2020
Integrin-Targeting Peptides for the Design of Functional Cell-Responsive Biomaterials.
Review in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 73 citations in OpenAlex.
- The potential and therapeutic advances of the integrin family in neurological disorders.Neural regeneration research · 2026Article
- The effect of liposomal ellagic acid on the biological properties of dental restorative materials: An in vitro comparative study.Biochemistry and biophysics reports · 2026Article
- Atomistic Insights into Graphene Oxide Dot Interactions with Integrin αNanomaterials (Basel, Switzerland) · 2026Article
- Cell-Penetrating Peptide-Mediated Modulation of Endoplasmic Reticulum Stress: A Bioengineered and Translational Approach.ACS pharmacology & translational science · 2026Review
- Safety Assessment of Extracellular Vesicle-Based Therapy in Regenerative Dentistry.International journal of molecular sciences · 2026Review
- Heterogeneous polymerization via two-step crosslinking for tunable microribbon hydrogels.Biofabrication · 2025Article
- Multiscale interface engineering in biohybrid composites for biomedical applications.Materials today. Bio · 2025Review
- Decoupling Bioactivity and Processability: RGD Click-Functionalized Coatings for a 3D-Printed PCL Scaffold.Biomacromolecules · 2025Article
- Peptide-Based Biomaterials as a Promising Tool for Cancer Radiotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Next-Generation Hydrogel Design: Computational Advances in Synthesis, Characterization, and Biomedical Applications.Polymers · 2025Review
- Biomaterials in tissue repair and regeneration: key insights from extracellular matrix biology.Frontiers in medical technology · 2025Review
- Current status of nano-embedded growth factors and stem cells delivery to bone for targeted repair and regeneration.Journal of orthopaedic translation · 2025Review
- Advancements in cyclodextrin-based controlled drug delivery: Insights into pharmacokinetic and pharmacodynamic profiles.Heliyon · 2024Review
- Scaffold-Mediated Drug Delivery for Enhanced Wound Healing: A Review.AAPS PharmSciTech · 2024Review
- The influence of a modified p53 C-terminal peptide by using a tumor-targeting sequence on cellular apoptosis and tumor treatment.Apoptosis : an international journal on programmed cell death · 2024Article
- Conjecturing about Small-Molecule Agonists and Antagonists of α4β1 Integrin: From Mechanistic Insight to Potential Therapeutic Applications.Biomedicines · 2024Review
- RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions.Cancer medicine · 2024Review
- One-step biofabrication of liquid core-GelMa shell microbeads forRegenerative biomaterials · 2024Article
- Use of pyridazinediones for tuneable and reversible covalent cysteine modification applied to peptides, proteins and hydrogels.Chemical science · 2023Article
- Extracellular matrix-induced signaling pathways in mesenchymal stem/stromal cells.Cell communication and signaling : CCS · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Integrins are a family of cell surface receptors crucial to fundamental cellular functions such as adhesion, signaling, and viability, deeply involved in a variety of diseases, including the initiation and progression of cancer, of coronary, inflammatory, or autoimmune diseases. The natural ligands of integrins are glycoproteins expressed on the cell surface or proteins of the extracellular matrix. For this reason, short peptides or peptidomimetic sequences that reproduce the integrin-binding motives have attracted much attention as potential drugs. When challenged in clinical trials, these peptides/peptidomimetics let to contrasting and disappointing results. In the search for alternative utilizations, the integrin peptide ligands have been conjugated onto nanoparticles, materials, or drugs and drug carrier systems, for specific recognition or delivery of drugs to cells overexpressing the targeted integrins. Recent research in peptidic integrin ligands is exploring new opportunities, in particular for the design of nanostructured, micro-fabricated, cell-responsive, stimuli-responsive, smart materials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.